Noxopharm Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2016
2017
2018
Cash & Short Term Investments
161.00
2,457.80
12,613.50
Total Accounts Receivable
38.90
62.60
122.60
Other Current Assets
106.30
46.80
70.50
Total Current Assets
306.10
2,567.30
14,075.70
Net Property, Plant & Equipment
16.60
64.40
317.80
Total Investments and Advances
-
0.80
118.80
Intangible Assets
-
0.80
37
Other Assets
-
195.40
-
Total Assets
322.70
2,828.60
14,549.30
Accounts Payable
283.20
290.60
Other Current Liabilities
13.60
70.40
Total Current Liabilities
296.90
361.00
Total Liabilities
296.90
361.00
Common Equity (Total)
25.90
2,467.50
Total Shareholders' Equity
25.90
2,467.50
Total Equity
25.90
2,467.50
Liabilities & Shareholders' Equity
322.70
2,828.60

About Noxopharm

View Profile
Address
828 Pacific Highway
Gordon New South Wales (NSW) 2072
Australia
Employees -
Website http://www.noxopharm.com
Updated 07/08/2019
Noxopharm Ltd. engages in the research and development of drugs. It focuses on sensitizing cancer cells to radiotherapy and chemotherapy. The company was founded by Graham Kelly on October 27, 2015 and is headquartered in Gordon, Australia.